Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.
Sebastian Stintzing
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche/Genentech
Honoraria - Amgen; Merck KGaA; Roche/Genentech; Sirtex Medical
Stefan Stremitzer
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Amgen; Bayer; Merck KGaA; Roche/Genentech; Sanofi
Honoraria - Bayer; Merck KGaA; Roche/Genentech; Sanofi
Research Funding - Amgen; Merck Serono; Roche/Genentech
Alfredo Falcone
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Yu Sunakawa
No relevant relationships to disclose
Satoshi Matsusaka
No relevant relationships to disclose
Shinichi Yamauchi
No relevant relationships to disclose
Wu Zhang
No relevant relationships to disclose
Dongyun Yang
No relevant relationships to disclose
Yan Ning
No relevant relationships to disclose
Ana Sebio
No relevant relationships to disclose
Diana L. Hanna
No relevant relationships to disclose
Saadat Siamak
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose